Kymera Therapeutics Receives U.S. FDA Fast Track Designation for Kt-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-cell Lymphoma and Relapsed/Refractory Peripheral T-cell Lymphoma

Kymera Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T cell Lymphoma and R/R Peripheral T cell Lymphoma.
[Kymera Therapeutics, Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News